Centene stock gains 1.08 percent as EPS guidance holds

Published on 09/29/2026 at 06:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Centene stock carries a USD 70.05 analyst target after the September 25, 2026 consensus update. Q2 revenue reached USD 53.58 billion, up 9.9 percent year over year.

Modernes Gesundheitszentrum-Gebäude mit Patienten am Eingang, Außenaufnahme, Tageslicht — Centene Corp. betreibt moderne ambulante Gesundheitszentren in den USA, ISIN US15133V1035 an der NYSE, Illustration mit AI erstellt.

Centene Corp. stock (ISIN US15133V1035) was last at USD 62.49 on the NYSE on September 28, 2026 at 3:59 p.m. ET, up 1.08 percent from the prior close of USD 61.82. The immediate company signal is earnings guidance: StockTitan reports that Centene reaffirmed its full-year 2026 GAAP diluted EPS guidance above USD 3.11 and adjusted diluted EPS guidance above USD 4.80 on September 16, 2026.

Guidance sets a measurable floor

The guidance gives Centene stock a clear earnings benchmark for the rest of 2026. The distinction between GAAP diluted EPS above USD 3.11 and adjusted diluted EPS above USD 4.80 also shows why investors must separate reported profitability from management's non-GAAP view.

Centene's second-quarter operating picture was more profitable than the prior-year comparison. According to MarketBeat on September 25, 2026, quarterly revenue reached USD 53.58 billion, up 9.9 percent year over year, while earnings per share came to USD 2.51 versus a USD 1.09 consensus estimate.

Analyst target stays above the quote

MarketBeat reports a consensus Hold rating from 21 brokerages and an average 12-month price target of USD 70.05, with recent targets ranging from USD 69.00 to USD 80.00. The average target lies 12.10 percent above the NYSE quote of USD 62.49, making the gap a concrete test of whether the earnings recovery can persist.

The same September 25 report identifies the central counterweight: Centene's latest quarterly result exceeded the USD 47.64 billion revenue consensus, but the stock still trades below the average target. That combination places greater weight on medical-cost control and the durability of the guidance than on revenue growth alone.

Centene stock remains tied to execution

Centene provides Medicaid, Medicare, Marketplace and Medicare-related healthcare coverage. Its investor-relations overview describes a business built around government-sponsored healthcare and local health plans, while its September 16 filing lists government payment changes, medical-cost trends and regulatory shifts among the factors that can affect results.

Centene stock was last at USD 62.49 on the NYSE on September 28, 2026 at 3:59 p.m. ET. Its 52-week range was USD 31.63 to USD 69.63, market capitalization was USD 30.9 billion, and volume was 4,932,838 shares.